Comparing ChromaDex (CDXC) and Stada Arzneimittel (STDAF)

ChromaDex (NASDAQ: CDXC) and Stada Arzneimittel (OTCMKTS:STDAF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Volatility & Risk

How to Become a New Pot Stock Millionaire

ChromaDex has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Stada Arzneimittel has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ChromaDex and Stada Arzneimittel, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChromaDex 0 0 2 0 3.00
Stada Arzneimittel 2 0 0 0 1.00

ChromaDex currently has a consensus target price of $7.50, indicating a potential upside of 84.73%. Given ChromaDex’s stronger consensus rating and higher possible upside, equities analysts clearly believe ChromaDex is more favorable than Stada Arzneimittel.

Profitability

This table compares ChromaDex and Stada Arzneimittel’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChromaDex -48.68% -52.15% -40.36%
Stada Arzneimittel N/A N/A N/A

Insider & Institutional Ownership

10.2% of ChromaDex shares are held by institutional investors. 11.6% of ChromaDex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares ChromaDex and Stada Arzneimittel’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChromaDex $21.20 million 10.50 -$11.37 million ($0.35) -11.60
Stada Arzneimittel $2.61 billion 2.54 N/A N/A N/A

Stada Arzneimittel has higher revenue and earnings than ChromaDex.

Summary

ChromaDex beats Stada Arzneimittel on 7 of the 12 factors compared between the two stocks.

About ChromaDex

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.

About Stada Arzneimittel

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications. The Branded Products segment offers APO-Go a Parkinson’s medicine; Aqualor for rhinitis/sore throat; Grippostad a cold medicine; Snup for rhinitis; and Vitaprost for prostate disease indications, as well as Ladival a sun protection product. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany.

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply